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Abstract  In  the  treatment  of  homozygous  and  therapy-




This  was  investigated  in  a  group  of  12  patients  using 



































factor  in  the  pathogenesis  of  atherosclerosis,  additional 
factors such as oxidative stress, adhesion molecules, and 
fibrinogen, which maintain atherosclerosis, influence endot-








































dismutase  (Cu/ZnSOD),  and  8-isoprostane-PGF2a  were 









The  single  H.E.L.P.  treatment  reduced  the  total  cho-








Following  the  H.E.L.P.  treatment,  in  most  patients  an 
increase in 8-isoprostane-PGF2a concentration in the serum 

































In  each  case,  the  reduction  in  the  plasma  concentration 





Pre Post1 Pre vs. post1 Post2 Pre vs. post2
OxLDL (mU/l) 11.4 ± 6 6.25 ± 3 p < 0.01 10 ± 3 n.s.
MDA (µmol/l) 1.27 ± 0.3 0.9 ± 0.14 p < 0.01 1.25 ± 02 n.s.
ImAnOx (µmol/l) 317 ± 35 287 ± 46 p = 0.03 312 ± 29 n.s.
Cu/ZnSOD (ng/ml) 75 ± 36 71 ± 27 n.s. 64 ± 20 n.s.



































with  hypercholesterolemia  and  angiographically  docu-













In  order  to  evaluate  coronary  vasodilatation  capacity, 






























At  the  time  of  the  follow-up  PET  examination  it  was 
1,19 ± 0.07 mPa s, corresponding to a reduction by 7.6%. 
This was also significant (p < 0.0075).




Group Cholesterol (mg/dl) LDL cholesterol (mg/dl) Fibrinogen (mg/dl)
PRE POST 1 POST 2 PRE POST 1 POST 2 PRE POST 1 POST 2
A 251 ± 58 120 ± 22 145 ± 28 175 ± 50 60 ± 21 77 ± 25 287 ± 75 102 ± 29 150 ± 52










































to  the  second  PET  examination  (reduction:  60.2/55.5%), 








and  normal  LDL  concentration,  a  high  MCR  is  particu-
larly conspicuous. A significant improvement in perfusion 
was  achieved  through  the  sharp  decrease  brought  about 
by H.E.L.P. apheresis. In all probability, Lp(a) in a high 
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